Working… Menu

The Combination Therapy With Ra-223 and Enzalutamide (CORE-OCU)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03305224
Recruitment Status : Recruiting
First Posted : October 9, 2017
Last Update Posted : April 9, 2019
Bayer Yakuhin, Ltd.
Information provided by (Responsible Party):
Taro Iguchi, MD, PHD, Osaka City University

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : December 31, 2019
Estimated Study Completion Date : June 30, 2021